- Home
- NMRA vs HEQ Comparison
NMRA vs HEQ Comparison
Compare NMRA & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- HEQ
- Stock Information
- Founded
- NMRA 2019
- HEQ 2011
- Country
- NMRA United States
- HEQ United States
- Employees
- NMRA N/A
- HEQ N/A
- Industry
- NMRA
- HEQ Investment Managers
- Sector
- NMRA
- HEQ Finance
- Exchange
- NMRA Nasdaq
- HEQ Nasdaq
- Market Cap
- NMRA 112.8M
- HEQ 127.0M
- IPO Year
- NMRA 2023
- HEQ N/A
- Fundamental
- Price
- NMRA $0.73
- HEQ $10.57
- Analyst Decision
- NMRA Buy
- HEQ
- Analyst Count
- NMRA 8
- HEQ 0
- Target Price
- NMRA $9.29
- HEQ N/A
- AVG Volume (30 Days)
- NMRA 846.2K
- HEQ 43.1K
- Earning Date
- NMRA 05-12-2025
- HEQ 01-01-0001
- Dividend Yield
- NMRA N/A
- HEQ 9.78%
- EPS Growth
- NMRA N/A
- HEQ N/A
- EPS
- NMRA N/A
- HEQ N/A
- Revenue
- NMRA N/A
- HEQ N/A
- Revenue This Year
- NMRA N/A
- HEQ N/A
- Revenue Next Year
- NMRA N/A
- HEQ N/A
- P/E Ratio
- NMRA N/A
- HEQ N/A
- Revenue Growth
- NMRA N/A
- HEQ N/A
- 52 Week Low
- NMRA $0.61
- HEQ $9.08
- 52 Week High
- NMRA $17.19
- HEQ $11.84
- Technical
- Relative Strength Index (RSI)
- NMRA 45.93
- HEQ 63.43
- Support Level
- NMRA $0.66
- HEQ $10.50
- Resistance Level
- NMRA $0.73
- HEQ $10.65
- Average True Range (ATR)
- NMRA 0.06
- HEQ 0.09
- MACD
- NMRA 0.01
- HEQ -0.01
- Stochastic Oscillator
- NMRA 59.70
- HEQ 82.50
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return with a focus on current income and gains and also consisting of long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.